Skip to main content

Table 3 Expansion of autoantibody antigenic targets related to primary biliary cholangitis along follow-up

From: Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies

Target

Timea

Groups

BN/AMA+ (n 59)

p

PBC (n 35)

p

Sp100b

T0

15 (25%)

0.097

4 (11%)

0.048

TX

19 (32%)

10 (29%)

Gp210b

T0

4 (7%)

1.000

3 (9%)

0.094

TX

4 (7%)

7 (20%)

CENP-A/CENP-Bb

T0

0 (0%)

0.317

6 (17%)

0.317

TX

1 (2%)

5 (14%)

PDC-E2/74 kDa-bandc

T0

42 (71%)

0.053

32 (91%)

0.317

TX

48 (81%)

31 (87%)

56 kDa-bandc

T0

3 (5%)

0.154

2 (6%)

0.074

TX

5 (8%)

5 (14%)

52 kDa-bandc

T0

25 (42%)

0.029

21 (60%)

1.000

TX

31 (53%)

21 (60%)

48 kDa-bandc

T0

6 (10%)

0.010

7 (20%)

0.094

TX

12 (20%)

11 (31%)

  1. BN/AMA+ biochemically normal individuals with positive AMA test, PBC patients with Primary Biliary Cholangitis
  2. aT0 is the baseline sample; TX is the sequential sample in which there was appearance of new autoantibody, which was variable among different individuals
  3. bDetermined by ELISA
  4. cDetermined by Western blot